Ale's World of Stocks on $FRNM

Ale's World of Stocks has discussed $FRNM in 1 video since 2026-11-15.

2026-11-15
“Google is Betting $1.2B on These 5 Crashing Stocks 🚨”
AI summary · FRNM is a neutral, not-yet-buy for the speaker. Its colon-cancer blood test is FDA-approved, its lung-cancer test has breakthrough designation and it has a rollout partner, but high sales growth has not reduced losses, which stay flat or worsen; U.S. colon-test sales sit with a partner that also owns a competing test, a conflict to monitor, and barriers to entry are low. He sees long-term potential but ranks FRNM slightly below a higher-growth peer (he would pick the peer from $1,000 of either despite FRNM's higher minimum price) and will not buy soon, needing several years of performance.

in the second deal, we have a brand new public company , probably unheard of by most ordinary investors, at least not yet. It is Freenome, a company specializing in cancer detection using artificial intelligence, and its code is FRNM.

Google currently owns about $30 million of its own shares after going public last July through a merger with a special purpose acquisition company (SPAC). Upon reviewing the stock chart, we find that it has experienced sharp fluctuations.

After a recent crash, its price has now stabilized at a level slightly below its initial public offering (IPO) levels .